Clinical Trials Logo

Major Depression clinical trials

View clinical trials related to Major Depression.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05477472 Completed - Major Depression Clinical Trials

Low Dose St John's Wort for Depression

Start date: August 2005
Phase:
Study type: Observational

This observational study observes the routine use of low-dose St John's Wort herbal mother tincture in patients with major depression. It measures intensity of depression at the beginning of St Johns Wort and after 6 weeks and evaluates tolerability and compliance.

NCT ID: NCT04446039 Completed - Major Depression Clinical Trials

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

Start date: July 4, 2022
Phase:
Study type: Observational

The primary purpose of this study is to investigate medication utilization pattern and risk of adverse outcomes among commonly used antidepressants by using nationwide claims database, in order to assess overall clinical benefit of antidepressant therapy in real-world practice.

NCT ID: NCT04388748 Completed - Major Depression Clinical Trials

Stress Management and Resiliency Training for Depression vs Treatment as Usual in the Treatment of Major Depression

Start date: December 18, 2020
Phase: N/A
Study type: Interventional

Researchers are trying to find out if a Stress Management and Resiliency Training (SMART-D) therapy will help with major depression treatment.

NCT ID: NCT04352101 Completed - Major Depression Clinical Trials

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

Start date: September 23, 2020
Phase: Phase 4
Study type: Interventional

This study is designed to determine whether bupropion (vs escitalopram) increases functional connectivity (FC) within reward-related neurocircuits and decreases motivational deficits in depressed patients with increased inflammation and anhedonia. Participants will be randomized to take bupropion extended release (XL) or escitalopram for 8 weeks.

NCT ID: NCT04235725 Completed - Major Depression Clinical Trials

Implementation of Harmonized Depression Outcome Measures in a Primary Care Registry and a Mental Health Registry

Start date: March 15, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this pilot project is to demonstrate feasibility and value of collecting harmonized outcomes measures for major depressive disorder (MDD) in two registries and combining the data to support patient-centered outcomes research.

NCT ID: NCT04235712 Completed - Major Depression Clinical Trials

Implementation of Harmonized Depression Outcome Measures in a Health System

Start date: November 17, 2020
Phase:
Study type: Observational

Working with a health system, the investigators will recruit practices to participate in the pilot study, consent and enroll patients with major depressive disorder, and collect the PHQ-9 from those patients at three timepoints (baseline, 6 months post-enrollment, and 12 months post-enrollment). The PHQ-9 will be captured either at an office visit or directly from patients. The investigators will build and implement an open-source SMART on FHIR app to collect key data from the EHR, combine that data with the PHQ-9 results, and present the measurements back to the clinicians. The investigators will then obtain feedback from clinicians on the value and usefulness of the app.

NCT ID: NCT04134871 Completed - Schizophrenia Clinical Trials

Walking for Health: an Intervention to Increase Physical Activity and Reduce Sedentary Behaviour in People With SMI

WORtH
Start date: August 22, 2019
Phase: N/A
Study type: Interventional

People who have a severe mental illness can have poorer physical health and higher mortality rates than the general population. Their medications combined with low levels of physical activity and increased sedentary behaviour can general population and may help people with severe mental illness to be more active. A previous feasibility study has been conducted in the UK in a large city with positive findings. The current study will be conducted in rural settings in Northern Ireland and Republic of Ireland. The intervention will last 13 weeks. People with Severe Mental Illness will be randomly assigned into one of two groups. Both groups will get information on the benefits of physical activity. In addition, one group will be shown how to use a step counter to measure their steps, be invited to a weekly group walk, and meet their coach every 2 weeks contribute to this. Walking is a good way to increase physical activity in the to see how they are getting on and to support them. The research team are interested in finding out how willing clinicians are to recruit people into the study, how willing people are to take part, do people then stick with the programme, and if not the reasons for people dropping out. Qualitative findings will explore whether participants feel they benefited from and enjoyed the programme. Findings will be used to investigate the feasibility to conduct a larger trial like this in the future.

NCT ID: NCT03927950 Completed - Major Depression Clinical Trials

Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment

Start date: January 2007
Phase: Phase 4
Study type: Interventional

The antidepressant medications are among the most commonly prescribed pharmacological agents in patients with mood and anxiety disorder. Despite recent advances in antidepressant pharmacotherapy, there is a pressing need for substantial optimization and improvment of outcome of pharmacotherapy of psychiatric disorders by providing individualized and science-based treatment guidelines. Besides it is rather difficult in clinical practice to predict, which patient will response to a certain pharmacological treatment well and which one less so. Putative predictors of response to antidepressant include demographic and clinical characteristics, personality traits, biological markers and psychophysiological features. Recently the research studies shown that divergences in antidepressant efficacy may be related to genetic variations of patients. The pharmacogenetic studies have multiplied in recent decade due to the impact that such studies may have in everyday clinical practice once reliable predictors could be identified. The pharmacogenetic research using new DNA microarray-based technology can reasonably be expected to contribute to the prediction of likelihood of treatment response and risk of development of adverse side effects in individual patients in case of antidepressant treatment. By reducing costly treatment failures and the likelihood of serious adverse events, pharmacogenetic testing may help to improve the treatment possibilities for chronic diseases, reduce the burden prescription drug costs, and lower the costs of drug development. The further detailed investigation of peripheral gene expression profiles may help to identify responsible genes that underlie the process of development of affective disorders and open novel horizons for understanding molecular mechanisms of psychopharmacological treatment.

NCT ID: NCT03913013 Completed - Bipolar Disorder Clinical Trials

Technology Enhanced Family Treatment

Start date: November 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The investigators propose to enhance the scalability of family-focused therapy (FFT), a 12-session evidence-based therapy for youth at high risk for mood disorders, through augmentation with a novel mobile phone application called MyCoachConnect (MCC). In adolescents with mood instability who have a parent with bipolar or major depressive disorder, clinicians in community clinics will conduct FFT sessions (consisting of psychoeducation and family skills training) supplemented by weekly MCC "real time" assessments of moods and family relationships; based on results of these assessments and the family's progress in treatment, clinicians will then push personalized informational and coaching alerts regarding the practice of communication and problem-solving skills. The investigators hypothesize that the augmented version of FFT (FFT-MCC) will be more effective than FFT without coaching/informational alerts in altering treatment targets and in stabilizing youths' mood symptoms and quality of life.

NCT ID: NCT03170362 Completed - Major Depression Clinical Trials

PRIME Care (PRecision Medicine In MEntal Health Care)

PRIME Care
Start date: June 15, 2017
Phase: N/A
Study type: Interventional

The focus of this application is on the impact of providing depressed Veterans and their providers with the results of pharmacogenetic (PGx) testing for psychotropic medications. The project focuses on whether and how patients and providers use genetic test results given to them at the time an antidepressant is to be initiated to treat Major Depressive Disorder (MDD) and whether use of the test results improves patient outcomes. MDD is one of the most common conditions associated with military service and combat exposure, increases suicide risk, and worsens the course of common medical conditions, making it a leading cause of functional impairment and mortality. Validation of a PGx test to personalize the treatment of MDD represents an important opportunity to improve the healthcare of Veterans.